MarketBeat
03 Sept 2026, 04:02 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Analysis by Kasper Rasmussen · Founder & analyst
What the story claims
4 claims · each scored for market impact
The FDA has accepted the new drug application for tinlarebant and granted it priority review with a PDUFA date of February 12, 2027. — FDA acceptance and priority review significantly increase the probability of approval and accelerate the timeline to commercialization.
+0.60If approved, tinlarebant would be the first and only approved treatment for Stargardt disease type 1. — First-mover advantage in an untapped market with no existing competition typically leads to high pricing power and rapid market penetration.
+0.50Phase III DRAGON trial results showed tinlarebant slowed the growth of DDAF lesions by approximately 35.7% compared to placebo (p=0.0033). — Statistically significant primary endpoint data provides the clinical evidence necessary to support FDA approval.
+0.40Continue reading
6 related stories
Search tags
Belite estimates a U.S. patient population of approximately 53,000 people with Stargardt disease type 1. — Defines the total addressable market (TAM), though the relatively small size characterizes this as an orphan drug opportunity.
+0.20Which stocks this story touches
The FDA accepted its new drug application for tinlarebant with priority review, and Phase III trial results showed a significant slowing of lesion growth.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
MarketBeat
5h ago
